NA-Selank vs Selank
Modified Anxiolytic Peptide · Anxiolytic Peptide
Here is how these two compounds compare, based on published research, not marketing claims.
NA-Selank
Selank with an N-acetyl modification for improved enzymatic stability; same mechanism, zero independent clinical validation.
Selank
The original tuftsin-derived anxiolytic peptide; Russian regulatory approval with published human clinical data.
NA-Selank
0 studies
0 human trials
Not FDA-Approved
Selank
88 studies
6 human trials
Not FDA-Approved
What it does
NA-Selank
Reduces anxiety through the same mechanism as Selank, with an N-acetyl modification designed to improve resistance to enzymatic breakdown and potentially increase nasal bioavailability.
Selank
Reduces anxiety without causing sedation, cognitive impairment, or dependence. Modulates the GABA system and enkephalin pathways to calm the stress response while preserving mental clarity.
How it works
NA-Selank
NA-Selank is Selank with an N-acetyl group attached to the N-terminus of the peptide chain. This modification is designed to protect the molecule from aminopeptidases, enzymes that break down peptides from the N-terminal end. The core pharmacology is identical to Selank: GABAergic modulation, enkephalin system amplification, serotonin metabolism influence, and BDNF expression increase. The modification changes how long the molecule survives in the body before being degraded, not how it works once it reaches its targets.
Selank
Selank is a synthetic heptapeptide derived from tuftsin, a naturally occurring immunomodulatory peptide. It modulates GABAergic signaling (the brain's primary inhibitory system), increases enkephalin activity (the body's own anxiety-reducing peptides), and influences serotonin metabolism. Unlike benzodiazepines, which also target GABA but cause sedation and dependence, Selank achieves anxiolytic effects without those liabilities. It also increases BDNF expression, a growth factor that supports synaptic plasticity and cognitive function.
How often
NA-Selank
NA-Selank is primarily available through research peptide markets as a nasal formulation. No regulatory approval exists in any country for NA-Selank specifically. No standardized dosing protocol has been established through clinical trials.
Selank
In Russian clinical practice, Selank is administered as a nasal spray. The compound received Russian regulatory approval for anxiolytic use. No FDA-approved product exists. Research protocols outside Russia primarily use nasal administration.
How strong
NA-Selank
The theoretical advantage is clear: improved stability should mean more of the active peptide reaches the brain intact after nasal administration. However, this advantage has not been independently validated in published human studies. Every efficacy claim about NA-Selank is extrapolated from Selank research, not from independent NA-Selank studies.
Selank
Anxiolytic effects documented in Russian human clinical studies with regulatory approval. The absence of sedation, cognitive impairment, and dependence liability distinguishes Selank from conventional anxiolytics. BDNF elevation provides a secondary cognitive support mechanism. The compound has both anxiolytic and nootropic properties in published research.
Main tradeoff
NA-Selank
Zero independent published research specific to NA-Selank. The N-acetyl modification is a pharmacokinetic improvement strategy, not a new drug. Safety and efficacy are assumed based on Selank data. Whether the improved stability translates to meaningfully better clinical outcomes has not been tested. Available only through research peptide markets.
Selank
Russian regulatory approval but limited Western clinical validation. Most published human data is in Russian-language literature with limited English-language replication. The compound has a favorable safety profile in published studies but the evidence base is geographically concentrated. Not FDA-approved. Available through research peptide markets and specialty compounding, not standard Western clinical channels.
Best for
NA-Selank
- Research on N-acetylation as a peptide stability enhancement strategy
- Research comparing modified-release peptide formulations to their parent molecules
- Research contexts where Selank's anxiolytic mechanism is the target but improved nasal bioavailability is desired
Selank
- Research on anxiolytic mechanisms that avoid sedation and dependence pathways
- Research on tuftsin-derived peptides and their immunomodulatory plus anxiolytic dual activity
- Research comparing Russian-approved peptide therapeutics to Western anxiolytic standards
How to choose
A good fit for NA-Selank
- Research on N-acetylation as a peptide stability enhancement strategy
- Research comparing modified-release peptide formulations to their parent molecules
- Research contexts where improved nasal bioavailability is specifically the variable under study
A good fit for Selank
- Research on anxiolytic peptide mechanisms with direct clinical evidence
- Research contexts where regulatory approval and published human safety data carry weight
- Research building on the existing published Selank clinical literature
Consider both across time
NA-Selank and Selank share the same pharmacology. The only difference is the N-acetyl modification on the N-terminus, which is designed to improve resistance to aminopeptidase degradation and potentially increase the amount of active peptide reaching the brain after nasal administration. Whether this theoretical stability advantage translates to meaningfully better clinical outcomes is unknown. Selank has the entire evidence base. NA-Selank has zero independent evidence. Cost and availability differences in the research peptide market may be a practical factor.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- N-Acetyl Stability Enhancement
- N-Acetyl Stability Enhancement enables GABAergic Modulation
- GABAergic Modulation amplifies Enkephalin System Modulation
- GABAergic Modulation increases BDNF Expression Increase
- Enkephalin System Modulation connects to Anxiety Reduction; BDNF Expression Increase connects to Anxiety Reduction; Serotonin Metabolism Adjustment connects to Anxiety Reduction
- N-Acetyl Stability Enhancement connects to Improved Nasal Bioavailability
- GABAergic Modulation modulates Serotonin Metabolism Adjustment
- BDNF Expression Increase connects to Cognitive Support
NA-Selank adds an N-acetyl group to Selank's N-terminus, protecting against aminopeptidase degradation for potentially improved nasal delivery.
Selank modulates GABAergic signaling and the enkephalin system to reduce anxiety without causing sedation or dependence.
Research Evidence
Selank has the entire evidence base for this pharmacological mechanism: Russian regulatory approval, published human clinical studies for anxiety and generalized anxiety disorder, animal studies across multiple models. NA-Selank has zero published studies that independently characterize its effects. Every efficacy claim about NA-Selank is extrapolated from Selank data. The N-acetyl modification has a pharmacokinetic rationale (improved stability), but this has not been validated in published human pharmacokinetic studies.
- 1.
For evidence-based anxiolytic use, selank has the published data and regulatory history.
- 2.
For potentially improved nasal bioavailability, NA-Selank's modification is designed for this purpose.
- 3.
For confidence in what you are using, selank has independent validation.
- 4.
For theoretical pharmacokinetic advantage, NA-Selank may deliver more active peptide per dose.
Key Limitations
- •NA-Selank has zero published research specific to the modified form.
- •Improved bioavailability is theoretical, not clinically demonstrated.
- •The price premium for NA-Selank may not reflect a proven advantage.
- •Both are limited by their Russian-centric evidence base.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
Selank
"Selank eliminated my anxiety without the side effects of benzodiazepines"
Plausible but unproven
"Nasal spray is the best way to take it"
Supported by published data
"It stacks well with Semax for cognitive performance"
Anecdotal only
Safety Comparison
Selank has published human safety data from Russian clinical use: non-sedating, non-addictive, no significant adverse effects reported. NA-Selank's safety is assumed based on Selank data, which is reasonable given the minor structural modification, but has not been independently confirmed. The N-acetyl group is a common pharmaceutical modification not expected to introduce novel toxicity, but the absence of dedicated safety data means this assumption is not clinically validated.
NA-Selank
Very limited safety data specific to NA-Selank. Safety profile inferred from selank research.
Selank
Approved in Russia. Reported as well-tolerated. No dependence liability.
What the Research Suggests
Selank has the research. NA-Selank has the theoretical advantage. Until independent data validates the modification, selank is the evidence-based choice.